Publications
Detailed Information
Comparison of Triple Antiplatelet Therapy Including Triflusal and Conventional Dual Therapy in Patients Who Underwent Drug-Eluting Stent Implantation
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Suh, Jung-Won | - |
dc.contributor.author | Kim, Song-Yi | - |
dc.contributor.author | Park, Jin-Shik | - |
dc.contributor.author | Kim, Yong-Seok | - |
dc.contributor.author | Koo, Bon-Kwon | - |
dc.contributor.author | Kim, Hyo-Soo | - |
dc.contributor.author | Kang, Hyun-Jae | - |
dc.date.accessioned | 2012-05-29T06:48:13Z | - |
dc.date.available | 2012-05-29T06:48:13Z | - |
dc.date.issued | 2009-11 | - |
dc.identifier.citation | INTERNATIONAL HEART JOURNAL; Vol.50 6; 701-709 | ko_KR |
dc.identifier.issn | 1349-2365 | - |
dc.identifier.uri | https://hdl.handle.net/10371/76559 | - |
dc.description.abstract | Triflusal is a derivative of acetylsalicylic acid but it exhibits different pharmacological and pharmacokinetic properties. The object of this study was to evaluate the efficacy of additional use of triflusal in patients who underwent drug-eluting stent implantation. First, we prospectively tested platelet function with a rapid platelet function analyzer (VerifyNow (R)-Aspirin) in patients with stable angina (male, age, 61.6 +/- 8.3, body weight, 69.3 +/- 11.2 kg) who maintained dual (aspirin 100 mg and clopidogrel 75 mg per clay, n = 23) or triple (aspirin 100 mg, clopidogrel 75 mg, and triflusal 300 mg per day, n = 23) therapy For more than one month. They were randomly assigned to a group. The triple group showed superior inhibition of arachidonic acid induced platelet aggregation compared to the dual group (420.2 +/- 47.7 ARU versus 465.0 +/- 71.2 ARU, P = 0.016). Second, we compared composite outcomes (death, myocardial infarction, and nonhemorrhagic stroke) after drug-eluting stent (DES) implantation between the dual (n = 1474) and triple (n = 433) groups in the prospective Seoul National University Hospital drug-eluting stent (SNUH-DES) cohort. The triple group had more current smokers, male patients, and patients with a previous history of revascularization. Also, the triple group underwent more complex interventions such as left main, chronic total occlusion, long lesion, and restenotic lesion than the dual group. In spite of their higher risk profiles, the triple group patients showed comparable composite outcomes (19 cases, 4.4%) to those of the dual group ones (41 cases, 2.8%) (P = 0.12). The triflusal-based triple antiplatelet therapy achieved superior platelet inhibition compared to the dual therapy ex vivo and it could be applied after complex intervention with DES. (Int Heart J 2009; 50: 701-709) | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | SPRINGER | ko_KR |
dc.subject | Triflusal | ko_KR |
dc.subject | Antiplatelet therapy | ko_KR |
dc.subject | Thrombosis | ko_KR |
dc.subject | Drug-eluting stent | ko_KR |
dc.title | Comparison of Triple Antiplatelet Therapy Including Triflusal and Conventional Dual Therapy in Patients Who Underwent Drug-Eluting Stent Implantation | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 서정원 | - |
dc.contributor.AlternativeAuthor | 김송이 | - |
dc.contributor.AlternativeAuthor | 박진식 | - |
dc.contributor.AlternativeAuthor | 김용석 | - |
dc.contributor.AlternativeAuthor | 강현재 | - |
dc.contributor.AlternativeAuthor | 구본권 | - |
dc.contributor.AlternativeAuthor | 김효수 | - |
dc.citation.journaltitle | INTERNATIONAL HEART JOURNAL | - |
dc.description.citedreference | Gomez-Isla T, 2008, ALZ DIS ASSOC DIS, V22, P21 | - |
dc.description.citedreference | Gurbel PA, 2007, CIRCULATION, V115, P3156, DOI 10.1161/CIRCULATIONAHA.106.675587 | - |
dc.description.citedreference | Suh JW, 2007, INT J CARDIOL, V117, P31, DOI 10.1016/j.ijcard.2006.03.009 | - |
dc.description.citedreference | Pamukcu B, 2006, J THROMB THROMBOLYS, V22, P103, DOI 10.1007/s11239-006-8952-4 | - |
dc.description.citedreference | Wang TH, 2006, EUR HEART J, V27, P647, DOI 10.1093/eurheartj/ehi684 | - |
dc.description.citedreference | Hankey GJ, 2006, LANCET, V367, P606, DOI 10.1016/S0140-6736(06)68040-9 | - |
dc.description.citedreference | Gurbel PA, 2005, J AM COLL CARDIOL, V46, P1827, DOI 10.1016/j.jacc.2005.07.056 | - |
dc.description.citedreference | Chen WH, 2005, AM J CARDIOL, V96, P760, DOI 10.1016/j.amjcard.2005.04.056 | - |
dc.description.citedreference | COSTA J, 2005, COCHRANE DB SYST REV, V20, P4296 | - |
dc.description.citedreference | Matetzky S, 2004, CIRCULATION, V109, P3171, DOI 10.1161/01.CIR.0000130846.46168.03 | - |
dc.description.citedreference | Culebras A, 2004, NEUROLOGY, V62, P1073 | - |
dc.description.citedreference | COLEMAN J, 2004, POINT CARE, V3, P77 | - |
dc.description.citedreference | Matias-Guiu J, 2003, STROKE, V34, P840, DOI 10.1161/01.STR.0000063141.24491.50 | - |
dc.description.citedreference | Bhatt DL, 2003, NAT REV DRUG DISCOV, V2, P15, DOI 10.1038/nrd985 | - |
dc.description.citedreference | Acarin L, 2002, STROKE, V33, P2499, DOI 10.1161/01.STR.0000028184.80776.58 | - |
dc.description.citedreference | ZAN S, 2002, MINERVA CARDIOANGIOL, V50, P263 | - |
dc.description.citedreference | de Miguel LS, 2000, EUR J CLIN INVEST, V30, P811 | - |
dc.description.citedreference | Cruz-Fernandez JM, 2000, EUR HEART J, V21, P457 | - |
dc.description.citedreference | de Arriba AF, 1999, MOL PHARMACOL, V55, P753 | - |
dc.description.citedreference | Bayon Y, 1999, BRIT J PHARMACOL, V126, P1359 | - |
dc.description.citedreference | McNeely W, 1998, DRUGS, V55, P823 | - |
dc.description.citedreference | de Miguel LS, 1998, EUR J PHARMACOL, V343, P57 | - |
dc.description.citedreference | LopezPousa S, 1997, REV NEUROLOGIA, V25, P1525 | - |
dc.description.citedreference | Cercek B, 1997, ATHEROSCLEROSIS, V131, P59 | - |
dc.description.citedreference | AUTERI A, 1995, INT J CLIN PHARM RES, V15, P57 | - |
dc.description.citedreference | PLAZA L, 1993, CARDIOLOGY, V82, P388 | - |
dc.description.citedreference | ESMATJES E, 1990, DIABETES CARE, V13, P1114 | - |
dc.description.citedreference | ESMATJES E, 1989, DIABETES RES CLIN PR, V7, P285 | - |
dc.description.citedreference | DECASTELLARNAU C, 1988, PROSTAG LEUKOTR ESS, V31, P83 | - |
dc.description.tc | 0 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.